https://www.selleckchem.com/products/iu1.html
The SSO Choosing Wisely campaign recommended selective sentinel lymph node biopsy (SLN in clinically node-negative women aged ≥ 70 years with ER+ breast cancer. We sought to assess the association of SLNB positivity, adjuvant treatment, and survival in a population-based cohort. Women aged ≥ 70 years treated for ER+ HER2- breast cancer between 2010 and 2016 were identified in our prospective provincial database. Overall survival (OS) and breast cancer-specific survival (BCSS) were assessed using Kaplan-Meier analysis. Multivariable logist
Aimer
Commentaire
Partagez
